Form 4: Penumbra Director Arani Bose Receives RSU Grant

Penumbra Inc. director Arani Bose was granted 589 restricted stock units, with vesting tied to service and potential acceleration upon a merger with Boston Scientific.

Summary

• Director Arani Bose of Penumbra Inc. was granted 589 restricted stock units (RSUs) on February 13, 2026.
• These RSUs are scheduled to vest in four equal installments (1/4 each) on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, contingent on Dr. Bose's continued service as a director.
• A significant condition for vesting acceleration is tied to a potential merger with Boston Scientific Corporation and Pinehurst Merger Sub, Inc., as per an agreement dated January 14, 2026. If this merger closes, any unvested RSUs will fully vest on the closing date, provided Dr. Bose remains a director.
• Dr. Bose directly holds 1,147 shares of common stock, a portion of which is subject to vesting.
• Additionally, Dr. Bose indirectly beneficially owns 258,462 shares of common stock through Bose Family Holdings II, LLC.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard director compensation and a potential M&A catalyst, but it's a routine disclosure rather than a significant operational update.

Positives

• Grant of 589 restricted stock units to a director aligns interests with shareholders.
• Potential for accelerated vesting of RSUs upon the closing of the merger with Boston Scientific Corporation provides an additional incentive.

Negatives

• The newly granted RSUs are subject to a vesting schedule, meaning they are not immediately available.
• A portion of the directly held 1,147 shares is also subject to vesting, indicating some illiquidity.

Risks

• The vesting of the 589 RSUs is contingent on Dr. Bose's continued service as a director through the specified vesting dates.
• The accelerated vesting of RSUs is dependent on the successful closing of the merger with Boston Scientific Corporation, which is not guaranteed.

Future Outlook

The future outlook for Dr. Bose's equity compensation is tied to his continued service as a director and the potential closing of a merger with Boston Scientific Corporation, which would accelerate the vesting of his restricted stock units.

Industry Context

StockSavvy.ai notes that equity grants to directors are a standard practice in the medical technology industry, aligning director interests with long-term shareholder value. The mention of a merger agreement with Boston Scientific Corporation suggests potential consolidation or strategic shifts within the competitive medical device landscape, which could impact Penumbra's market position and future operations.

Stakeholder Impact

• Shareholders: The RSU grant aligns director interests with shareholder value. The potential merger with Boston Scientific Corporation could significantly impact shareholder value, depending on the terms.
• Employees: The merger, if it occurs, could have implications for employees, though not directly detailed in this filing.

Next Steps

• Continued service of Dr. Bose as a director through vesting dates.
• Potential closing of the merger with Boston Scientific Corporation, which would trigger accelerated RSU vesting.
• Regular vesting of RSUs on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, if the merger does not close earlier.

Key Dates

Recommendation

While the RSU grant is a routine compensation event, the explicit mention of a merger agreement with Boston Scientific Corporation introduces significant uncertainty and potential upside/downside. Investors should hold and await further details on the merger, as its outcome will be the primary driver of stock performance rather than this specific insider transaction.

Keywords

Penumbra Inc, PEN, Arani Bose, Form 4, SEC Filing, Restricted Stock Units, RSU, Director Compensation, Insider Trading, Beneficial Ownership, Boston Scientific, Merger Agreement, Equity Grant